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Abstract 
 
In this paper we investigated the influence on affinity, selectivity and intrinsic activity upon 
modification of the adenosine agonist scaffold at the 3’- and 5’-positions of the ribofuranosyl 
moiety and the 2 and N6-positions of the purine base. This resulted in the synthesis of various 
analogues, i.e. 3-12 and 24-33, with good hA3AR selectivity and moderate-to-high affinities 
(as in 32, Ki = 27 nM). Interesting was the ability to tune the intrinsic activity depending on 
the substituent introduced at the 3’-position. 
 
Keywords: adenosine receptors; nucleoside analogues; binding; efficacy. 
 
1. Introduction 
 
G protein-coupled receptors (GPCRs) with their typical seven-helix transmembrane (7TM) 
domains, constitute a large group of integral membrane proteins. Interacting with structurally 
diverse extracellular signals, GPCRs provide a molecular link for activation (or inhibition) of 
intracellular processes via given signal transduction pathways1 and represent the most 
prominent family of validated drug targets.2
The regulatory actions of adenosine are mediated by four subtypes of GPCRs called 
adenosine receptors (ARs) that are ubiquitously expressed in the body and can be 
distinguished as A1, A2A, A2B and A3 receptors.3 Activation of the A3AR subtype, which is 
distributed in various organs (lung, liver, kidney, heart and brain),4 has been shown to mediate 
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adenylate cyclase inhibition5 and phospholipase C6 and D7 stimulation. All four AR subtypes 
have been characterised on a pharmacological level as well as on a molecular level.8 ARs 
from different species show a high degree of amino acid sequence homology (82-93%) with 
the only exception being the A3AR subtype, which only exhibits 74% primary sequence 
homology between rat and human or sheep.9-10 To be of therapeutic value, synthetic AR 
ligands need to be highly selective for a given receptor subtype and tissue targeted. Although 
several agonists have been synthesized that are selective for the known ARs subtypes,3,11 so 
far the only AR agonist approved for clinical use is adenosine itself. In this paper we focus on 
the human (h)A3AR subtype, the most recently identified member of the AR family.12-14 
The A3AR, plays a crucial role in some of the physiological effects of adenosine.15,16 In 
addition to cardio-17-19 and cerebroprotective effects,20,21 hA3AR agonists may be 
therapeutically useful for the treatment of stroke,22 inflammation23 and in cancer therapy.24 
While full agonists maximally stimulate the receptor, partial agonists show reduced intrinsic 
activity, may exhibit fewer side effects25,26 and may induce less receptor down-regulation and 
desensitisation than full agonists.15 Partial A3AR agonists can act as cardioprotective agents.27 
Selective antagonists for the A3AR promise to be useful in the regulation of cell growth28,29 
and as anti-asthmatic,30 cerebroprotective20,31 and anti-inflammatory agents.32 
Since its discovery in 1991,12 the development of agonists of the A3AR has been an active 
area of research. Many variations have been made on the adenosine scaffold in view of potent 
and selective A3AR binding.11,15,33 Generally, substitution at the 2’- and 8-positions has 
affinity- and efficacy-lowering effects.11,15 Known A3AR-selective alterations relevant to the 
work presented in this paper are N6-modifications, such as 3-iodobenzyl (IB)11,15,33,34 or 5-
chloro-2-methoxybenzyl (CMB),35 and smaller substituents like a Cl or CN at the 2-position33-
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35 of the purine moiety. Both the 2- and N6-purine modifications have been described with and 
without the 5’-methylcarbamoyl (MEC)33 insertion in the nucleoside sugar moiety . 
Combinations of these groups are often additive in their potency enhancement and resulted in 
potent and moderately selective A3AR agonists, such as Cl-IB-MECA and IB-MECA,36 
which are still used as reference tools for pharmacological study of the A3AR. 
 
Investigated to a lesser extent are 3’-modifications of the ribofuranosyl moiety.37,38 We and 
others have shown that a 3’-amino substitution opens perspectives towards influencing the 
hA3AR selectivity.39,40 This stimulated us to investigate the effect on both affinity and 
efficacy of this 3’-amino modification when combined with the above mentioned variations at 
the 5’-, 2- and N6-positions (derivatives 27, 29 and 32). By introducing an -oriented 
methylene spacer (the so-called branching) between the 3’-carbon of the ribofuranosyl moiety 
and the amine functional group (derivatives 7-10, 28 and 33), we aimed to modulate the 
hydrogen bond-donating effects of the 3’-amine, known to be crucial from our neoceptor 
work.39,41 With this work we wanted to provide more insight into the effect of 3’, 5’, 2- and 
N6-positional variations of the adenosine nucleoside scaffold on hA3AR affinity and to 
investigate the impact of such a combined substitution pattern on the hA3AR efficacy. 
 
2. Results and discussion 
 
2.1. Chemistry 
 
The synthesis of the simple 3’-branched N6-modified adenosine analogues is depicted in 
Scheme 1. Starting from the commercially available 1,2-O-isopropylidene-D-xylofuranose (1)
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the 3’-C-azidomethyl synthon 2 was prepared according to our recently reported procedure.41 
Displacement of the 6-chloro atom with ammonia, methylamine, 3-iodobenzylamine or 5-
chloro-2-methoxybenzyl-amine,42 followed by deprotection with methanolic ammonia 
produced the 3’-C-azidomethyl nucleosides 3-6. This chloropurine coupling strategy was 
found to be superior to the coupling with the N6-modified purines.39 Triphenylphosphine 
reduction of the azido moiety gave the 3’-C-aminomethyl nucleosides 7, 8, 941 and 10.
Amidation of 9, 10 was performed using an acyl chloride under Schotten-Baumann conditions 
and furnished derivatives 11 and 12.
Scheme 1. 
 
For the synthesis of the modified analogues in Scheme 2, the 3--azido (1543,44) and 3-C--
azidomethyl (1645) sugars were obtained by simple 5’-deprotection of the previously 
described intermediates 1339 and 14.41 Periodate oxidation46 followed by esterification of the 
carboxylic acid and subsequent treatment with methylamine in a pressure tube47 afforded the 
ribofuronamides 1740 and 18. A one-pot deprotection-acetylation strategy afforded the 
peracylated sugar moieties 19 and 20 modified at the 3’,5’-positions. 
Scheme 2. 
 
As pointed out in Scheme 3, deprotection of 17 with 70% acetic acid and subsequent 
acetylation, using an acetic anhydride-pyridine (1:2) mixture, resulted in the rearrangement 
formation of compound 35 (via 34). Vorbrüggen-coupling48 of 19 and 20 (in Scheme 2) with 
silylated 6-chloropurine and 2,6-dichloropurine49 quantitatively yielded the key synthons 21-
23. Selective displacement of the 6-chloro atom of 21-23 with 3-iodobenzylamine and 5-
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chloro-2-methoxybenzylamine, followed by deprotection with methanolic ammonia produced 
the 3’-azido (24, 26 and 30) and 3’-C-azidomethyl (25 and 31) nucleosides. 
Triphenylphosphine reduction of the azido moieties smoothly furnished the respective amino 
nucleosides 27-29, 32 and 33.
Scheme 3. 
 
2.2. Biological activity 
 
Modifications of the adenosine scaffold known to increase hA3AR binding affinity and 
selectivity among adenosine agonists include: a 5’-uronamide moiety (as in 24-33) and 
substitutions at the 2- (as in 26 and 29) and N6-positions (as in 4-6 and 8-33). In this paper we 
investigated the influence on hA3AR affinity and intrinsic activity of combining these 5’, 2- 
and N6-modifications with the amino(methyl) substitution at the 3’-position that we39,41 and 
others40 recently reported.  
 
Generally, substitution of the 2’- and 3’-hydroxyl groups of the ribofuranose moiety of AR 
agonists has been avoided. It has been demonstrated that modification of the 2’-position, 
compared to the 3’-position, had a negative impact on both potency and intrinsic 
activity.37,38,50 However, a 3’-amino modification was recently shown to be beneficial for 
hA3AR selectivity depending on the overall substitution pattern of the adenosine nucleoside.40 
This prompted us to investigate the boundaries of this 3’-amino substitution by insertion of a 
methylene spacer between the ribofuranose ring and the amine functional group. 
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Table 1. 
 
2.2.1. Affinity and Selectivity 
 
Looking at the analogues that exhibited < 1 µM affinities (in Table 1), it was clear that the 5’-
uronamide modification for both the direct and branched-chain amine (as in 24-33 vs. 3-12)
improved the overall affinity. With exception of 5 and 9, all compounds evaluated showed 
very good selectivity for the hA3AR subtype. In the simple 3’-amino series the most potent 
compound 32 (Ki = 27 nM) showed a 300-fold selectivity over the A1AR, compared to the 22-
fold selectivity for its N6-iodobenzyl substituted analogue 27. Introduction of a chloro atom at 
the 2-position resulted in the selective and moderately potent (Ki = 132 nM) partial agonist 29.
All branched-chain analogues on the other hand had a good hA3AR selectivity profile, but 
displayed weak binding characteristics, e.g. analogue 33 with a Ki of 557 nM having the 
highest affinity in this series. Introduction of the methylene spacer also affected intrinsic 
activity (see section 2.2.2.). In both the 3’-amino and 3’-aminomethyl series the affinity of the 
azido precursors was lower. This affinity difference was striking especially for the N6-
iodobenzyl substituted analogues: 24 (Ki = 2260 nM) vs. 27 (Ki = 137 nM) and 26 (Ki = 4270 
nM) vs. 29 (Ki = 132 nM). 
 
Focusing on the N6-substituents, known to be important for hA3AR selectivity,36 we observed 
a difference between the simple 3’-amino and branched-chain 3’-aminomethyl series, 
depending on the modification at the 5’-position. In the 5’-hydroxy 3’-amino series, 3’-
amino-N6-iodobenzyladenosine (Ki = 870 nM) showed a significant 500-fold potency 
enhancement compared to 3’-aminoadenosine (Ki = 442 µM). In the 5’-hydroxy branched-
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chain series (as in 3-12), however, contrary to what we recently reported for simple N6-
substituted adenosine analogues,35 N6-(5-chloro-2-methoxybenzyl) substitution (as in 10, Ki =
13.8 µM) did not improve affinity over the N6-iodobenzyl modification (as in 9, Ki = 8.7 µM). 
The reduction of hA3AR affinity upon acetamide formation (as in analogues 11 and 12)
indicated that introduction of a 3’-branching was the sterically maximal allowed modification. 
 
In the 5’-uronamide series, both for the 3’-amino and branched-chain 3’-aminomethyl 
analogues, the influence of N6-substitution on hA3AR binding was consistent with our 
previous findings,35 i.e. N6-iodobenzyl (as in 27, 28 and 29 with Ki = 137 nM, 1.7 µM and 132 
nM respectively) was less affinity-enhancing than N6-(5-chloro-2-methoxybenzyl) (as in 32
and 33 with Ki = 27 nM and 557 nM respectively). 
 
2.2.2. Intrinsic activity 
 
The results of the cyclic AMP-assay (in Table 1) indicated that all analogues were strong 
partial agonists at best. In the simple 5’-hydroxy 3’-amino series, 3’-aminoadenosine and 3’-
amino-N6-iodobenzyladenosine are known full agonists.39 The 5’-uronamide analogues 27
and 32 were partial agonists, contrary to what was reported earlier.40 
In the 3’-branched-chain series, comparison of the 5’-hydroxy derivatives 5, 9 and 10 with the 
5’-uronamides 25, 28 and 33, demonstrated a moderate influence of the 5’-methyluronamide 
modification on intrinsic activity. Thus, in general, introduction of a 3’-branching reduced the 
efficacy and, contrary to efficacy-reducing substitutions at the N6 and 2-positions,33,38 this 
effect could only partially be overcome by modification of the 5’-position. 
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A modification known to have contradictory effects on A3AR binding and intrinsic activity is 
the introduction of a chlorine at the 2-position.33 Comparing 27 with the 2-chloro substituted 
29, this modification did not alter the affinity nor the efficacy in this series.  
 
An overall conclusion is that, contrary to the 3’-aminomethyl modification, the simple 3’-
amino is better tolerated in terms of affinity and efficacy, resulting at best in (strong) partial 
agonists with moderate binding properties (as in analogues 27, 29 and 32) and low hA3AR 
affinity antagonists for the branched-chain derivatives, with exception of 33. In both series, 
the azido precursors (as in compounds 3-5, 24-26, 30 and 31) were full antagonists.  
 
The 3’-amino modification has hydrogen bond donor properties, like the 3’-hydroxyl 
group,33,39 whereas for the 3’-azido, like the 3’-F,37 this hydrogen bond pattern is no longer 
possible, resulting in a drop of efficacy.38 For the branched-chain series, this difference in 
efficacy between the 3’-azidomethyl and 3’-aminomethyl analogues was less clear, which is 
most likely due to the steric impact of this modification. 
 
3. Conclusion 
 
From a pharmacological point of view the modulation of hA3AR activity by selective 
agonists, partial agonists and antagonists is very important. In this paper we investigated the 
influence on affinity, selectivity and intrinsic activity of combined modifications at the 3’- 
and 5’-positions of the ribofuranosyl moiety with purine modifications at the 2- and N6-
positions. Various synthetic analogues, i.e. 3-12 and 24-33, displayed good hA3AR selectivity 
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and moderate-to-high affinities. More interesting, however, was the ability to tune the efficacy 
depending on the substituent introduced at the 3’-position. A 3’-amino function (as in 27, 29
and 32) resulted in (strong) partial agonist activity, whereas the azide precursors (as in 24, 26
and 30) converted these analogues into antagonists. Introduction of a methylene spacer 
between these functionalities and the ribofuranose ring (as in 3-12, 25, 28, 31 and 33) had an 
overall efficacy- and affinity-lowering effect. 
 
The (branched-chain) amino and azido modifications at the 3’-position presented herein, open 
interesting perspectives towards tuning the efficacy and selectivity for the A3AR, starting 
from the adenosine nucleoside agonist scaffold. The analogues reported in this paper also 
represent valuable tools for the further exploration of the neoceptor concept, i.e. investigation 
of molecular complementarity at mutant A2A41 and A339 adenosine receptors.  
 
4. Experimental Part 
 
4.1. Synthesis 
 
1H NMR spectra were obtained with a Varian 300 MHz spectrometer. The solvent signal of 
CDCl3 (7.26 ppm) and DMSO-d6 (2.50 ppm) were used as a secondary reference. Assignment 
of all 1H-resonances was confirmed by 2D 1H-1H COSY experiments. All signals assigned to 
amino and hydroxyl groups were exchangeable with D2O. Exact mass measurements were 
performed on a quadrupole/orthogonal-acceleration time-of-flight (Q/oaTOF) tandem mass 
spectrometer (qTOF 2, Micromass, Manchester, UK) equipped with a standard electrospray 
ionisation (ESI) interface. Samples were infused in a 2-propanol:water (1:1) mixture at 3 
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µl/min. Elemental analyses were performed at the University of Konstanz, Germany, and are 
within ±0.4% of theoretical values unless otherwise specified. 
 
General procedure for the synthesis of the N6-substituted nucleosides 3-6, 24-26, 30 and 
31 from the chloropurine derivatives 2, 21, 22 and 23. An amount of the appropriate 
chloropurine and the appropriate amine salt (or ammonia in the case of 3) (1.5 eq.), were 
dissolved in EtOH (15 mL / mmol chloropurine) containing Et3N (1.25 eq.). The reaction 
mixture was refluxed overnight and evaporated to dryness. The residue was dissolved in 7 N 
NH3 in MeOH (ca. 30 mL), stirred for 24 h at room temperature and evaporated in vacuo.
Precipitation from MeOH and subsequent filtration for 3-6 or purification by silica gel 
chromatography (CH2Cl2-MeOH) for 24-26, 30 and 31 furnished the desired product as a 
white pure solid. 
 
4.2. 9-(3-C-Azidomethyl-3-deoxy--D-ribofuranosyl)-adenine (3). 
300 mg (0.62 mmol) of 2 yielded 80 mg (42%) of 3: 1H NMR (DMSO-d6)  2.58-2.67 (m, 
1H, H-3’), 3.44 (dd, 1H, J = 5.7 Hz and -12.4 Hz, 3’-CHb), 3.53 (ddd, 1H, J = 3.8 Hz and 5.9 
Hz and -12.2 Hz, H-5B’), 3.65 (dd, 1H, J = 8.2 Hz, 3’-CHa), 3.73 (ddd, 1H, J = 3.0 Hz and 
5.1 Hz, H-5A’), 3.99 (dt, 1H, J = 3.2 Hz and 8.6 Hz, H-4’), 4.54-4.58 (m, 1H, H-2’), 5.22 (t, 
1H, J = 5.5 Hz, 5’-OH), 5.91 (d, 1H, J = 2.1 Hz, H-1’), 6.04 (d, 1H, J = 4.6 Hz, 2’-OH), 7.29 
(s, 2H, 6-NH2), 8.13 and 8.39 (2s, 2H, H-2 and H-8); exact mass (ESI-MS) calculated for 
C11H15N8O3 [M+H]+: 307.1267, found 307.1270. Anal. (C11H14N8O3.1/4 H2O) C,H,N. 
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4.3. 9-(3-C-Azidomethyl-3-deoxy--D-ribofuranosyl)-N6-methyladenine (4). 
400 mg (0.82 mmol) of 2 yielded 180 mg (68%) of 4: 1H NMR (DMSO-d6)  2.58-2.68 (m, 
1H, H-3’), 2.93 (br s, 3H, N6-CH3), 3.44 (dd, 1H, J = 5.6 Hz and -12.31 Hz, 3’-CHb), 3.53 
(ddd, 1H, J = 3.7 Hz, 5.7 Hz and -12.2 Hz, H-5B’), 3.64 (dd, 1H, J = 7.9 Hz, 3’-CHa), 3.73 
(ddd, 1H, J = 2.9 Hz and 5.3 Hz, H-5A’), 3.99 (dt, 1H, J = 3.2 Hz and 8.8 Hz, H-4’), 4.55 (dt, 
1H, J = 2.1 Hz and 5.2 Hz, H-2’), 5.23 (t, 1H, J = 5.4 Hz, 5’-OH), 5.92 (d, 1H, J = 2.3 Hz, H-
1’), 6.05 (d, 1H, J = 5.0 Hz, 2’-OH), 7.78 (s, 1H, N6-H), 8.22 and 8.39 (2s, 2H, H-2 and H-8); 
exact mass (ESI-MS) calculated for C12H17N8O3 [M+H]+: 321.1423, found 321.1429. Anal. 
(C12H16N8O3.2/3 H2O) C,H,N. 
 
4.4. 9-(3-C-Azidomethyl-3-deoxy--D-ribofuranosyl)-N6-(3-iodobenzyl)adenine (5). 
340 mg (0.69 mmol) of 2 yielded 227 mg (62%) of 5: 1H NMR (DMSO-d6)  2.59-2.68 (m, 
1H, H-3’), 3.44 (dd, 1H, J = 5.6 Hz and -12.3 Hz, 3’-CHb), 3.54 (ddd, 1H, J = 3.7 Hz, 5.6 Hz 
and -12.3 Hz, H-5B’), 3.64 (dd, 1H, J = 8.2 Hz, 3’-CHa), 3.73 (ddd, 1H, J = 2.9 Hz and 5.3 
Hz, H-5A’), 4.00 (dt, 1H, J = 3.2 Hz and 8.6 Hz, H-4’), 4.55-4.59 (m, 1H, H-2’), 4.64 (br s, 
2H, N6-CH2-Ar), 5.20 (t, 1H, J = 5.6 Hz, 5’-OH), 5.93 (d, 1H, J = 2.1 Hz, H-1’), 6.05 (d, 1H, 
J = 5.0 Hz, 2’-OH), 7.05 (t, 1H, J = 7.8 Hz, Ar-H-5), 7.34 (d, 1H, J = 7.9 Hz, Ar-H-6), 7.56 
(d, 1H, J = 8.2 Hz, Ar-H-4), 7.70 (s, 1H, Ar-H-2), 8.20 and 8.44 (2s, 2H, H-2 and H-8), 8.46 
(br s, 1H, N6-H); exact mass (ESI-MS) calculated for C18H20IN8O3 [M+H]+: 523.0704, found 
523.0698. Anal. (C18H19IN8O3) C,H,N. 
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4.5. 9-(3-C-Azidomethyl-3-deoxy--D-ribofuranosyl)-N6-(5-chloro-2-methoxybenzyl) 
adenine (6). 
300 mg (0.62 mmol) of 2 yielded 100 mg (35%) of 6: 1H NMR (DMSO-d6)  2.61-2.70 (m, 
1H, H-3’), 3.45 (dd, 1H, J = 5.7 Hz and -12.3 Hz, 3’-CHb), 3.55 (ddd, 1H, J = 3.7 Hz, 5.4 Hz 
and -12.2 Hz, H-5B’), 3.65 (dd, 1H, J = 8.1 Hz, 3’-CHa), 3.75 (ddd, 1H, J = 2.9 Hz and 5.0 
Hz, H-5A’), 3.83 (s, 3H, Ar-OCH3), 4.01 (dt, 1H, J = 3.2 Hz and 8.7 Hz, H-4’), 4.63 (m, 3H, 
H-2’ and N6-CH2-Ar), 5.16 (t, 1H, J = 5.4 Hz, 5’-OH), 5.95 (d, 1H, J = 2.1 Hz, H-1’), 6.01 (d, 
1H, J = 5.0 Hz, 2’-OH), 7.01 (d, 1H, J = 8.8 Hz, Ar-H-3), 7.08 (br s, 1H, Ar-H-6), 7.24 (dd, 
1H, J = 2.6 and 8.8 Hz, Ar-H-4), 8.19 (br s, 2H, H-2 and N6-H), 8.44 (s, 1H, H-8); exact mass 
(ESI-MS) calculated for C19H22ClN8O4 [M+H]+: 461.1452, found 461.1460. Anal. 
(C19H21ClN8O4) C,H,N. 
 
4.6. 9-[3-Azido-3-deoxy-5-(methylcarbamoyl)--D-ribofuranosyl]-N6-(3-iodobenzyl) 
adenine (24). 
300 mg (0.79 mmol) of 21 yielded 250 mg (60%) of 24; Spectroscopic data of this compound 
in accordance with those reported in ref. 40; Anal. (C18H18IN9O3.3/2 H2O) C,H,N. 
 
4.7. 9-[3-C-Azidomethyl-3-deoxy-5-(methylcarbamoyl)--D-ribofuranosyl]-N6-(3-
iodobenzyl)adenine (25). 
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300 mg (0.75 mmol) of 22 yielded 360 mg (73%) of 25: 1H NMR (DMSO-d6)  2.63 (d, 3H, J 
= 4.4 Hz, CH3-N), 2.75-2.84 (m, 1H, H-3’), 3.50 (dd, 1H, J = 5.9 Hz and -12.3 Hz, 3’-CHb), 
3.71 (dd, 1H, J = 7.9 Hz, 3’-CHa), 4.33 (d, 1H, J = 8.5 Hz, H-4’), 4.63 (m, 3H, H-2’ and N6-
CH2-Ar), 6.03 (d, 1H, J = 2.1 Hz, H-1’), 6.15 (d, 1H, J = 4.7 Hz, 2’-OH), 7.09 (t, 1H, J = 7.8
Hz, Ar-H-5), 7.35 (d, 1H, J = 7.6 Hz, Ar-H-6), 7.57 (d, 1H, J = 7.9 Hz, Ar-H-4), 7.71 (s, 1H, 
Ar-H-2), 8.24 (m, 2H, H-2 and NH-CO), 8.43 (br s, 1H, N6-H), 8.55 (s, 1H, H-8); exact mass 
(ESI-MS) calculated for C19H21IN9O3 [M+H]+: 550.0813, found 550.0803. Anal. 
(C19H20IN9O3.3/2 H2O) C,H,N. 
 
4.8. 2-Chloro-9-[3-azido-3-deoxy-5-(methylcarbamoyl)--D-ribofuranosyl]-N6-(3-
iodobenzyl)adenine (26). 
200 mg (0.48 mmol) of 23 yielded 210 mg (77%) of 26: 1H NMR (DMSO-d6)  2.69 (d, 3H, J
= 4.1 Hz, CH3-N), 4.35 (d, 1H, J = 2.9 Hz, H-4’), 4.47 (t, 1H, J = 4.1 Hz, H-3’), 4.60 (brs, 2H, 
N6-CH2-Ar), 4.92 (app d, 1H, J = 4.9 Hz, H-2’), 5.92 (d, 1H, J = 6.2 Hz, H-1’), 6.31 (d, 1H, J
= 4.7 Hz, 2’-OH), 7.12 (t, 1H, J = 7.8 Hz, Ar-H-5), 7.35 (d, 1H, J = 7.3 Hz, Ar-H-6), 7.59 (d, 
1H, J = 7.9 Hz, Ar-H-4), 7.74 (s, 1H, Ar-H-2), 8.25 (d, 1H, J = 4.1 Hz, NH-CO), 8.49 (s, 1H, 
H-8), 8.99 (brs, 1H, N6-H); exact mass (ESI-MS) calculated for C18H17ClIN9O3Na [M+Na]+:
592.0087, found 592.0092. Anal. (C18H17ClIN9O3.1/2 H2O) C,H,N. 
 
4.9. 9-[3-Azido-3-deoxy-5-(methylcarbamoyl)--D-ribofuranosyl]-N6-(5-chloro-2-
methoxybenzyl)adenine (30). 
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300 mg (0.79 mmol) of 21 yielded 251 mg (67%) of 30: 1H NMR (DMSO-d6)  2.68 (d, 3H, J
= 4.7 Hz, CH3-N), 3.83 (s, 3H, Ar-OCH3), 4.34 (d, 1H, J = 3.2 Hz, H-4’), 4.49 (dd, 1H, J =
3.2 Hz and 5.3 Hz, H-3’), 4.65 (br s, 2H, N6-CH2-Ar), 4.97 (q, 1H, J = 5.6 Hz and 11.1 Hz, H-
2’), 6.00 (d, 1H, J = 6.5 Hz, H-1’), 6.29 (d, 1H, J = 5.3 Hz, 2’-OH), 7.00 (d, 1H, J = 9.08 Hz, 
Ar-H-3), 7.08 (br s, 1H, Ar-H-6), 7.24 (dd, 1H, J = 2.8 Hz and 8.6 Hz, Ar-H-4), 8.25 (s, 1H, 
H-2), 8.35 (br s, 1H, N6-H), 8.47 (s, 1H, H-8), 8.62 (d, 1H, J = 4.7 Hz, NH-CO); exact mass 
(ESI-MS) calculated for C19H21ClN9O4 [M+H]+: 474.1404, found 474.1400. Anal. 
(C19H20ClN9O4.1/2 H2O) C,H,N. 
 
4.10. 9-[3-Azidomethyl-3-deoxy-5-(methylcarbamoyl)--D-ribofuranosyl]-N6-(5-chloro-2-
methoxybenzyl)adenine (31). 
300 mg (0.75 mmol) of 22 yielded 300 mg (82%) of 31: 1H NMR (DMSO-d6)  2.63 (d, 3H, J
= 4.4 Hz, CH3-N), 2.76-2.85 (m, 1H, H-3’), 3.50 (dd, 1H, J = 5.9 Hz and -12.4 Hz, 3’-CHb), 
3.71 (dd, 1H, J = 7.8 Hz, 3’-CHa), 3.83 (s, 3H, Ar-OCH3), 4.32 (d, 1H, J = 8.8 Hz, H-4’), 4.60 
(br s, 3H, N6-CH2-Ar and H-2’), 6.04 (s, 1H, H-1’), 6.21 (d, 1H, J = 4.7 Hz, 2’-OH), 7.00 (d, 
1H, J = 8.8 Hz, Ar-H-3), 7.05 (br s, 1H, Ar-H-6), 7.24 (dd, 1H, J = 2.6 Hz and 8.5 Hz, Ar-H-
4), 8.21 (s, 1H, H-2), 8.30 (d, 1H, J = 4.7 Hz, NH-CO), 8.36 (brs, 1H, N6-H), 8.60 (s, 1H, H-
8); exact mass (ESI-MS) calculated for C20H23ClN9O4 [M+H]+: 488.15661, found 488.1559. 
Anal. (C20H22ClN9O4.1/2 H2O) C,H,N. 
 
General procedure for the synthesis of the amino nucleosides 7, 8, 9, 10, 27-29, 32 and 33 
from their azido precursors 3-6, 24-26, 30 and 31. The azido nucleoside was dissolved in 
dry pyridine (8 mL / mmol) and PhP3 (1.6 eq.) was added to the solution. After stirring at 
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room temperature for 1.5 h, concentrated NH4OH (3 mL / mmol) was added. The reaction 
mixture was stirred for another 2 h, evaporated to dryness and purified by silica gel 
chromatography (CH2Cl2-MeOH). 
 
4.11. 9-(3-C-Aminomethyl-3-deoxy--D-ribofuranosyl)-adenine (7). 
60 mg (0.20 mmol) of 3 furnished 35 mg (64%) of 7 as a white solid: 1H NMR (DMSO-d6)
 2.31-2.40 (m, 1H, H-3’), 2.65 (dd, 1H, J = 6.2 Hz and -12.6 Hz, 3’-CHb), 2.89 (dd, 1H, J =
7.3 Hz, 3’-CHa), 3.56 (dd, 1H, J = 3.2 Hz and -11.9 Hz, H-5B’), 3.68 (dd, 1H, J = 4.0 Hz, H-
5A’), 3.98 (dt, 1H, J = 3.7 Hz and 9.4 Hz, H-4’), 4.50 (dd, 1H, J = 1.5 Hz and 5.3 Hz, H-2’), 
5.88 (d, 1H, J = 1.5 Hz, H-1’), 7.27 (s, 2H, 6-NH2), 8.12 and 8.36 (2s, 2H, H-2 and H-8); 
exact mass (ESI-MS) calculated for C11H17N6O3 [M+H]+: 281.1362, found 281.1370. Anal. 
(C11H16N6O3) C,H,N. 
 
4.12. 9-(3-C-Aminomethyl-3-deoxy--D-ribofuranosyl)-N6-methyladenine (8). 
100 mg (0.31 mmol) of 4 furnished 64 mg (70%) of 8 as a white solid: 1H NMR (DMSO-d6)
 2.26-2.35 (m, 1H, H-3’), 2.62 (dd, 1H, J = 6.5 Hz and -12.6 Hz, 3’-CHb), 2.87 (dd, 1H, J =
7.0 Hz, 3’-CHa), 2.93 (br s, 3H, N6-CH3), 3.56 (dd, 1H, J = 3.5 Hz and -11.9 Hz, H-5B’), 3.67 
(dd, 1H, J = 4.3 Hz, H-5A’), 3.99 (dt, 1H, J = 3.8 Hz and 9.1 Hz, H-4’), 4.50 (dd, 1H, J = 1.6
Hz and 5.1 Hz, H-2’), 5.88 (d, 1H, J = 1.8 Hz, H-1’), 7.75 (s, 1H, N6-H), 8.21 and 8.34 (2s, 
2H, H-2 and H-8); exact mass (ESI-MS) calculated for C12H19N6O3 [M+H]+: 295.1518, found 
295.1513. Anal. (C12H18N6O3.3/2 H2O) C,H,N. 
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4.13. 9-(3-C-Aminomethyl-3-deoxy--D-ribofuranosyl)-N6-(3-iodobenzyl)adenine (9). 
200 mg (0.38 mmol) of 5 furnished 131 mg (69%) of 9 as a white solid: Spectroscopic data of 
this compound in accordance with those reported in ref. 41; Anal. (C18H21IN6O3) C,H,N. 
 
4.14. 9-(3-C-Aminomethyl-3-deoxy--D-ribofuranosyl)-N6-(5-chloro-2-methoxybenzyl) 
adenine (10). 
90 mg (0.17 mmol) of 6 furnished 54 mg (64%) of 10 as a white solid: 1H NMR (DMSO-d6)
 2.29-2.38 (m, 1H, H-3’), 2.65 (dd, 1H, J = 6.3 Hz and -12.5 Hz, 3’-CHb), 2.89 (dd, 1H, J =
7.0 Hz, 3’-CHa), 3.57 (dd, 1H, J = 3.5 Hz and -11.9 Hz, H-5B’), 3.69 (dd, 1H, J = 4.1 Hz, H-
5A’), 3.83 (s, 3H, Ar-OCH3), 4.01 (dt, 1H, J = 3.9 Hz and 9.0 Hz, H-4’), 4.55 (dd, 1H, J = 1.2 
Hz and 5.0 Hz, H-2’), 4.65 (br s, 2H, N6-CH2-Ar), 5.91 (d, 1H, J = 1.5 Hz, H-1’), 7.00 (d, 1H, 
J = 8.8 Hz, Ar-H-3), 7.07 (d, 1H, J = 2.3 Hz, Ar-H-6), 7.24 (dd, 1H, J = 2.6 Hz and 8.8 Hz, 
Ar-H-4), 8.18 (br s, 2H, H-2 and N6-H), 8.40 (s, 1H, H-8); exact mass (ESI-MS) calculated 
for C19H24ClN6O4 [M+H]+: 435.1547, found 435.1546. Anal. (C19H23ClN6O4.1/4 H2O) 
C,H,N. 
 
4.15. 9-[3-Amino-3-deoxy-5-(methylcarbamoyl)--D-ribofuranosyl]-N6-(3-iodobenzyl) 
adenine (27). 
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176 mg (0.33 mmol) of 24 furnished 30 mg (18%) of 27 as a white solid: Spectroscopic data 
of this compound in accordance with those reported in ref. 40; Anal. (C18H20IN7O3.1/2 H2O) 
C,H,N. 
 
4.16. 9-[3-C-Aminomethyl-3-deoxy-5-(methylcarbamoyl)--D-ribofuranosyl]-N6-(3-
iodobenzyl)adenine (28). 
100 mg (0.18 mmol) of 25 furnished 45 mg (48%) of 28 as a white solid: 1H NMR (DMSO-
d6)  2.41-2.47 (m, 1H, H-3’), 2.64 (d, 3H, J = 4.7 Hz, CH3-N), 2.76 (dd, 1H, J = 5.3 Hz and -
12.3 Hz, 3’-CHb), 2.90 (dd, 1H, J = 7.6 Hz, 3’-CHa), 4.34 (d, 1H, J = 8.8 Hz, H-4’), 4.55 (dd, 
1H, J = 2.1 Hz and 5.3 Hz, H-2’), 4.66 (br s, 2H, N6-CH2-Ar), 6.00 (d, 1H, J = 2.4 Hz, H-1’), 
7.09 (t, 1H, J = 7.8 Hz, Ar-H-5), 7.35 (d, 1H, J = 7.9 Hz, Ar-H-6), 7.56 (d, 1H, J = 7.6 Hz, 
Ar-H-4), 7.71 (s, 1H, Ar-H-2), 8.22 (s, 1H, H-2), 8.29 (d, 1H, J = 4.7 Hz, NH-CO), 8.42 (br s, 
1H, N6-H), 8.62 (s, 1H, H-8); exact mass (ESI-MS) calculated for C19H23IN7O3 [M+H]+:
524.0908, found 524.0912. Anal. (C19H22IN7O3.3/4 H2O) C,H,N. 
 
4.17. 2-Chloro-9-[3-amino-3-deoxy-5-(methylcarbamoyl)--D-ribofuranosyl]-N6-(3-
iodobenzyl)adenine (29). 
200 mg (0.35 mmol) of 26 furnished 140 mg (74%) of 29 as a white solid: 1H NMR (DMSO-
d6)  2.67 (d, 3H, J = 4.7 Hz, CH3-N), 3.54 (t, 1H, J = 5.6 Hz, H-3’), 4.11 (d, 1H, J = 5.9 Hz, 
H-4’), 4.31 (t, 1H, J = 4.1 Hz, H-2’), 4.59 (brs, 2H, N6-CH2-Ar), 5.95 (d, 1H, J = 3.5 Hz, H-
1’), 7.11 (t, 1H, J = 7.8 Hz, Ar-H-5), 7.35 (d, 1H, J = 7.6 Hz, Ar-H-6), 7.59 (d, 1H, J = 7.6
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Hz, Ar-H-4), 7.73 (s, 1H, Ar-H-2), 8.15 (d, 1H, J = 4.1 Hz, NH-CO), 8.61 (s, 1H, H-8), 8.93 
(brs, 1H, N6-H); exact mass (ESI-MS) calculated for C18H20ClIN7O3 [M+H]+: 544.0362,
found 544.0366. Anal. (C18H19ClIN7O3) C,H,N. 
 
4.18. 9-[3-Amino-3-deoxy-5-(methylcarbamoyl)--D-ribofuranosyl]-N6-(5-chloro-2-
methoxybenzyl)adenine (32). 
176 mg (0.33 mmol) of 30 furnished 29 mg (20%) of 32 as a white solid: 1H NMR (DMSO-
d6)  2.67 (d, 3H, J = 4.7 Hz, CH3-N), 3.57 (t, 1H, J = 5.4 Hz, H-3’), 3.83 (s, 3H, Ar-OCH3), 
4.12 (d, 1H, J = 5.9 Hz, H-4’), 4.38 (t, 1H, J = 4.5 Hz, H-2’), 4.65 (br s, 2H, N6-CH2-Ar), 6.02 
(d, 1H, J = 4.1 Hz, H-1’), 7.00 (d, 1H, J = 8.8 Hz, Ar-H-3), 7.08 (br s, 1H, Ar-H-6), 7.20 (dd, 
1H, J = 2.6 Hz and 8.8 Hz, Ar-H-4), 8.23 (s, 1H, H-2), 8.29 (br s, 1H, N6-H), 8.44 (d, 1H, J =
5.0 Hz, NH-CO), 8.57 (s, 1H, H-8); exact mass (ESI-MS) calculated for C19H23ClN7O4
[M+H]+: 448.1499, found 448.1483. Anal. (C19H22ClN7O4.3/2 H2O) C,H,N. 
 
4.19. 9-[3-Aminomethyl-3-deoxy-5-(methylcarbamoyl)--D-ribofuranosyl]-N6-(5-chloro-
2-methoxybenzyl)adenine (33). 
150 mg (0.31 mmol) of 31 furnished 100 mg (70%) of 33 as a white solid: 1H NMR (DMSO-
d6)  2.40-2.48 (m, 1H, H-3’), 2.64 (d, 3H, J = 4.7 Hz, CH3-N), 2.76 (dd, 1H, J = 5.1 Hz and -
12.8 Hz, 3’-CHb), 2.90 (dd, 1H, J = 7.9 Hz, 3’-CHa), 3.83 (s, 3H, Ar-OCH3), 4.34 (d, 1H, J =
9.1 Hz, H-4’), 4.55 (dd, 1H, J = 1.6 Hz and 5.1 Hz, H-2’), 4.62 (br s, 2H, N6-CH2-Ar), 6.01 
(d, 1H, J = 1.8 Hz, H-1’), 7.00 (d, 1H, J = 8.8 Hz, Ar-H-3), 7.04 (s, 1H, Ar-H-6), 7.24 (dd, 
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1H, J = 2.6 Hz and 8.8 Hz, Ar-H-4), 8.20 (s, 1H, H-2), 8.35 (br d, 2H, J = 4.7 Hz, NH-CO and 
N6-H), 8.68 (s, 1H, H-8); exact mass (ESI-MS) calculated for C20H25ClN7O4 [M+H]+:
462.1652, found 462.1657. Anal. (C20H24ClN7O4.3/2H2O) C,H,N. 
 
Procedure for the amidation of 9 and 10 under Schotten-Baumann conditions. To a 
solution of the appropriate amine in THF (10 mL / mmol) were added 50% aqueous NaOAc 
solution (10 mL / mmol) and an acetyl chloride (0.9 eq.). After completion of reaction (6 h), 
THF and brine were added. The organic phase was separated, washed with water, dried over 
MgSO4 and concentrated in vacuo. Precipitation from MeOH and subsequent filtration 
furnished the product as a white solid in 60-63% yield. 
 
4.20. 9-(3-Acetamidomethyl-3-deoxy--D-ribofuranosyl)-N6-(3-iodobenzyl)adenine (11). 
70 mg (0.14 mmol) of 9 yielded 48 mg (63 %) of 11: 1H NMR (DMSO-d6)  1.77 (s, 3H, 
CH3), 2.46 (m, 1H, H-3’), 3.08-3.16 (m, 1H, 3’-CHb), 3.24-3.30 (m, 1H, 3’-CHa), 3.54 (ddd, 
1H, J = 3.4 Hz, 5.3 Hz and -12.5 Hz, H-5B’), 3.77 (ddd, 1H, J = 2.6 Hz and 5.0 Hz, H-5A’), 
3.97 (dt, 1H, J = 2.8 Hz and 9.4 Hz, H-4’), 4.41 (t, 1H, J = 4.0 Hz, H-2’), 4.63 (br s, 2H, N6-
CH2-Ar), 5.22 (t, 1H, J = 5.3 Hz, 5’-OH), 5.85 (d, 1H, J = 4.4 Hz, H-1’), 5.93 (d, 1H, J = 1.2
Hz, 2’-OH), 7.09 (t, 1H, J = 7.8 Hz, Ar-H-5), 7.34 (d, 1H, J = 7.6 Hz, Ar-H-6), 7.56 (d, 1H, J 
= 7.9 Hz, Ar-H-4), 7.70 (s, 1H, Ar-H-2), 7.89 (t, 1H, J = 5.4 Hz, 3’-C-NH), 8.20 (s, 1H, H-2), 
8.47 (2s, 2H, H-8 and N6-H); exact mass (ESI-MS) calculated for C20H24IN6O4 [M+H]+:
539.0905, found 539.0890. Anal. (C20H23IN6O4.3/2 H2O) C,H,N. 
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4.21. 9-(3-Acetamidomethyl-3-deoxy--D-ribofuranosyl)-N6-(5-chloro-2-methoxybenzyl) 
adenine (12). 
10 mg (0.023 mmol) of 10 yielded 6.6 mg (60 %) of 11: 1H NMR (DMSO-d6)  1.79 (s, 3H, 
CH3), 3.10-3.19 (m, 1H, H-3’), 3.27-3.36 (m, 1H, 3’-CHb), 3.51-3.60 (m, 1H, 3’-CHa), 3.77-
3.84 (m, 5H, H-5B’, H-5A’ and Ar-OCH3), 4.00 (m, 1H, H-4’), 4.45 (app s, 1H, H-2’), 4.65 
(brs, 2H, N6-CH2-Ar), 5.22 (t, 1H, J = 5.1 Hz, 5’-OH), 5.87 (d, 1H, J = 4.4 Hz, H-1’), 5.95 (d, 
1H, J = 1.5 Hz, 2’-OH), 7.02 (d, 1H, J = 8.8 Hz, Ar-H-3), 7.07 (s, 1H, Ar-H-6), 7.25 (dd, 1H, 
J = 2.8 Hz and 8.7 Hz, Ar-H-4), 7.90 (t, 1H, J = 5.3 Hz, 3’-C-NH), 8.20 (s, 1H, H-2), 8.26 
(brs, 1H, N6-H), 8.49 (s, 1H, H-8); exact mass (ESI-MS) calculated for C21H26ClN6O5
[M+H]+: 477.1653, found 477.1641. Anal. (C21H25ClN6O5.1/2H2O) C,H,N. 
 
4.22. Methyl 3-azido-3-deoxy-1,2-isopropylidene--D-ribofuronamide (17)40.
A biphasic mixture of water (46 mL), CHCl3 (31 mL) and acetonitrile (31 mL) containing 
compound 1543,44 (3.3 g, 15.33 mmol), RuCl3 hydrate (160 mg, 0.77 mmol) and NaIO4 (13.45 
g, 62.87 mmol) was vigorously stirred for 4.5 h at room temperature. The reaction mixture 
was then diluted with water (100 mL) and extracted with CH2Cl2 (3 x 200 mL). The combined 
organic phase was dried over MgSO4, filtrated and evaporated. A dark green oily residue was 
triturated with diethyl ether to precipitate the ruthenium salts, that were removed by filtration 
through celite. The filtrate was concentrated in vacuo, leaving 2.7 g (76.8%) 3-azido-3-deoxy-
1,2-isopropylidene--D-ribofuronic acid as a lightly coloured oil that was used without further 
purification. A mixture of 3-azido-3-deoxy-1,2-isopropylidene--D-ribofuronic acid (2.5 g, 
11.78 mmol), EDC (5.2 mL, 29.5 mmol) and DMAP (145 mg, 1.2 mmol) in anhydrous 
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methanol (50 mL) was stirred at room temperature for 24 h. The reaction mixture was 
concentrated to dryness and the residue was dissolved in CH2Cl2 (200 mL) and water (100 
mL). The aqueous phase was extracted with CH2Cl2 (3 x 200 mL) and the combined organic 
phase was dried over MgSO4, filtered and evaporated. The residue was dissolved in 2 M 
methylamine in THF (20 mL) and was heated for 24 h at 55°C in a sealed tube. After cooling, 
the reaction mixture was concentrated to dryness and purified by silica gel chromatography 
(pentane-EtOAc) to give 17 (1.2 g, 32.5%) as a transparent oil. Spectroscopic data of this 
compound in accordance with those reported in ref. 40. 
 
4.23. Methyl 3-azidomethyl-3-deoxy-1,2-isopropylidene--D-ribofuronamide (18). 
 
Compound 18 (1.3 g, 32%) was prepared from 1645 (3.6 g, 15.7 mmol) in analogy to the 
procedure described for 17: 1H NMR (CDCl3)  1.34 and 1.49 (2s, 6H, 2 x CH3), 2.15-2.25 
(m, 1H, H-3), 2.80 (d, 3H, J = 5.0 Hz, CH3-N), 3.64 (dd, 1H, J = 11.1 Hz and -12.1 Hz, 3-
CHb), 3.87 (dd, 1H, J = 4.3 Hz, 3-CHa), 4.15 (d, 1H, J = 10.6 Hz, H-4), 4.73 (t, 1H, J = 3.8
Hz, H-2), 5.85 (d, 1H, J = 5.5 Hz, H-1), 6.50 (br s, 1H, NH-CO); exact mass (ESI-MS) 
calculated for C10H17N4O4 [M+H]+: 257.1249, found 257.1253. 
 
4.24. 9-[2-O-Acetyl-3-C-azido-3-deoxy-5-(methylcarbamoyl)--D-ribofuranose]-6-
chloropurine (21). 
A mixture of 17 (1.2 g, 5 mmol), concentrated sulphuric acid (1.47 mL, 27.5 mmol) and 
acetic anhydride (4.95 mL, 52.4 mmol) in glacial acid (25 mL) was stirred for 18 h at room 
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temperature. After cooling in an ice bath, saturated NaHCO3 solution (50 mL) and CH2Cl2 (50 
mL) were slowly added and the mixture was stirred for another 10 min. After separation the 
aqueous phase was extracted with CH2Cl2 (3 x 100 mL). The combined organic phase was 
washed with saturated NaHCO3 solution and brine, dried over MgSO4, filtered and evaporated 
to dryness to yield 787 mg (55%) of the crude methyl 3-azido-3-deoxy-1,2-diacetyl--D-
ribofuronamide (19) as a yellowish foam: 1H NMR (DMSO-d6)  2.01 and 2.10 (2s, 6H, 2 x 
CH3), 2.79 (d, 3H, J = 5.0 Hz, CH3-N), 4.33-4.43 (m, 2H, H-3 and H-4), 5.24 (dd, 1H, J = 0.8
Hz and 5.0 Hz, H-2), 6.07 (br s, 1H, H-1), 6.53 (d, 1H, J = 4.7 Hz, NH-CO). Compound 19 
(0.78 g, 2.72 mmol) was used to prepare the title compound (987 mg, 95%) in analogy to the 
procedure described for 2. Spectroscopic data of this compound in accordance with those 
reported in ref. 40. 
 
4.25. 9-[2-O-Acetyl-3-C-azidomethyl-3-deoxy-5-(methylcarbamoyl)--D-ribofuranose]-6-
chloropurine (22). 
From 18 (1.3 g, 5 mmol), in analogy to the procedure described for 19, the methyl 3-
azidomethyl-3-deoxy-1,2-diacetyl--D-ribofuronamide (0.6 g, 40%) was prepared: 1H NMR 
(CDCl3)  2.06 and 2.13 (2s, 6H, 2 x CH3), 2.74-2.77 (m, 1H, H-3), 2.81 (d, 3H, J = 5.0 Hz, 
CH3-N), 3.55 (dd, 1H, J = 10.5 Hz and -12.3 Hz, 3-CHb), 3.91 (dd, 1H, J = 4.4 Hz, 3-CHa), 
4.28 (d, 1H, J = 9.7 Hz, H-4), 5.23 (d, 1H, J = 4.7 Hz, H-2), 6.12 (s, 1H, H-1), 6.41 (d, 1H, J
= 4.1 Hz, NH-CO). This acetylated ribofuronamide (0.6 g, 2 mmol) was used to prepare the 
title compound (750 mg, 95%) in analogy to the procedure described for 2. 1H NMR (CDCl3)
 2.20 (s, 3H, CH3), 2.83 (d, 3H, J = 5.0 Hz, CH3-N), 3.38-3.48 (m, 1H, H-3’), 3.73 (dd, 1H, J
= 9.1 Hz and -12.6 Hz, 3’-CHb), 3.87 (dd, 1H, J = 4.4 Hz, 3’-CHa), 4.48 (d, 1H, J = 9.4 Hz, 
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H-4’), 5.62 (dd, 1H, J = 2.5 Hz and 6.6 Hz, H-2’), 6.09 (d, 1H, J = 2.3 Hz, H-1’), 6.98 (d, 1H, 
J = 4.4 Hz, NH-CO), 8.22 and 8.75 (2s, 2H, H-2 and H-8); exact mass (ESI-MS) calculated 
for C14H16ClN8O4 [M+H]+: 395.0982, found 395.0982. 
 
4.26. 9-[2-O-Acetyl-3-C-azido-3-deoxy-5-(methylcarbamoyl)--D-ribofuranose]-2,6-
dichloropurine (23). 
Compound 19 (200 mg, 0.69 mmol) was coupled with silylated 2,6-dichloropurine in analogy 
to the procedure described for 2, to yield the the title compound 23 (200 mg, 70%): 1H NMR 
(CDCl3) S 2.10 (s, 3H, CH3), 2.63 (d, 3H, J = 4.7 Hz, CH3-N), 4.52 (d, 1H, J = 5.6 Hz, H-4’), 
4.93 (t, 1H, J = 5.6 Hz, H-3’), 5.96 (t, 1H, J = 4.7 Hz, H-2’), 6.37 (d, 1H, J = 3.8 Hz, H-1’), 
8.16 (d, 1H, J = 4.4 Hz, NH-CO), 8.99 (s, 1H, H-8); exact mass (ESI-MS) calculated for 
C13H12Cl2N8O4 [M+H]+: 437.0256, found 437.0252. 
 
4.27. Acetic acid 5-acetoxy-4-azido-2-(6-chloro-purin-9-yl)-1-methyl-6-oxo-pipedin-3-yl 
ester (35).  
 
0.75 g (3.0 mmol) of 17 was dissolved in 70% HOAc (30 mL). The solution was kept at 60°C 
and after 48 h the reaction mixture was evaporated to dryness. The residue was dissolved in a 
acetic anhydride-pyridine (2:1) mixture (50 mL). After 3 h, the mixture was partitioned 
between CH2Cl2 (100 mL) and 7% NaHCO3 (150 mL). The aqueous layer was washed with 
CH2Cl2 (150 mL) and the combined organic layers were dried with MgSO4, filtered and 
evaporated in vacuo. Treatment with a hexane-EtOAc mixture allowed precipitation of 0.6 g 
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(61%) of acetic acid 3,5-diacetoxy-4-azido-6-oxo-piperidin-2-yl ester (34) as a white solid: 1H
NMR (CDCl3)  2.11, 2.16 and 2.34 (3s, 9H, CH3), 2.91 (s, 3H, N-CH3), 4.35 (t, 1H, J = 3.4 
Hz, H-4), 5.24 (dd, 1H, J = 3.8 Hz and 4.7 Hz, H-3), 5.57 (d, 1H, J = 2.9 Hz, H-5), 6.09 (d, 
1H, J = 5.0 Hz, H-2). Compound 34 (0.58 g, 1.8 mmol) was used to prepare the title 
compound (710 mg, 93%) in analogy to the procedure described for 2. 1H NMR (CDCl3)
 1.99 and 2.30 (2s, 6H, 2 x CH3), 2.66 (s, 3H, N-CH3), 4.51 (t, 1H, J = 2.8 Hz, H-3’), 5.82 
(d, 1H, J = 7.9 Hz, H-5’), 5.97 (dd, 1H, J = 2.6 Hz and 7.9 Hz, H-4’), 6.01 (d, 1H, J = 2.9 Hz, 
H-2’), 8.24 and 8.79 (2s, 2H, H-2 and H-8); exact mass (ESI-MS) calculated for 
C15H16ClN8O5 [M+H]+: 423.0932, found 423.0934. 
 
4.28. Elemental Analysis 
 
Table 2. 
 
4.29. Biological assays 
 
4.29.1. Cell culture and membrane preparation 
 
CHO cells expressing recombinant human and rat A3ARs were cultured in DMEM 
(Dulbecco’s modified Eagle’s medium) and F12 (1:1) supplemented with 10% fetal bovine 
serum, 100 units/mL penicillin, 100 µg/mL streptomycin, 2 µmol/mL glutamine, and 800 
µg/mL geneticin. After harvest and homogenization, the cells were centrifuged at 500g for 10 
min. The pellet was resuspended in 50 mM Tris–HCl buffer (pH 8.0) containing 10 mM 
MgCl2 and 1mM EDTA. The suspension was homogenized with an electric homogenizer for 
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10 sec, and was then recentrifuged at 20,000g for 20 min at 4 °C. The resulting pellets were 
resuspended in buffer containing 3 units/mL of adenosine deaminase, and the suspension was 
stored at -80 °C prior to the binding experiments. The rat A3AR was expressed recombinantly 
via transfection in CHO cells, and the procedure was the same as for the human subtype. The 
protein concentration was measured using the Bradford assay.51 
4.29.2. Binding assay 
 
For the A3AR binding experiments, the procedures used were similar to those previously 
described.33 Briefly, each tube contained 100 µL of membrane suspension, 50 µL of [125I]I-
AB-MECA (final concentration 0.5 nM), and 50 µL of increasing concentrations of 
compounds in Tris–HCl buffer (50 mM, pH7.4) containing 10 mM MgCl2, 1mM EDTA. 
Nonspecific binding was determined using 10 µM NECA (5’-N-ethyluronamidoadenosine). 
The mixtures were incubated at 25 °C for 60 min. Binding reactions were terminated by 
filtration through Whatman GF/B filters under reduced pressure using a MT-24 cell harvester 
(Brandel, Gaithersburg, MD). Filters were washed three times with ice-cold buffer. 
Radioactivity was determined in a Beckman 5500B -counter. The binding of [3H]RPIA to the 
recombinant hA1AR and the binding of [3H]CGS21680 to the recombinant hA2AAR was 
performed as previously described.34,52 
4.29.3. Cyclic AMP accumulation assay 
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Intracellular cyclic AMP levels were measured with a competitive protein binding method.53 
CHO cells expressing recombinant human4 and rat13 ARs were harvested by trypsinization. 
After resuspension in the medium, cells were plated in 24-well plates in 0.5 mL medium/well. 
After 24 h, the medium was removed and cells were washed three times with 1 mL/well of 
DMEM, containing 50 mM N-2-hydroxyethylpiperazine-N’-2- ethanesulfonic acid, pH 7.4. 
Cells were then treated with agonists and/or test compounds in the presence of rolipram (10 
µM) and adenosine deaminase (3 units/mL) and incubated at 37 °C. For A2A and A2BARs, 
incubation was carried out for 1 h. For A1 and A3ARs, after 45 min forskolin (10 µM) was 
added to the medium, and incubation was continued for an additional 15 min. The reaction 
was terminated upon removal of the medium, and the cells were lysed with 200 µL/well of 0.1 
M ice cold HCl. The cell lysate was resuspended and stored at -20 °C. For determination of 
cyclic AMP production, protein kinase A (PKA) was incubated with [3H]cyclic AMP (2nM) 
in K2HPO4/EDTA buffer (K2HPO4, 150mM; EDTA, 10 mM), 20 µL of the cell lysate, and 
30 µL 0.1M HCl. Bound radioactivity was separated by rapid filtration through Whatman 
GF/C filters under reduced pressure and washed once with cold buffer. Bound radioactivity 
was subsequently measured by liquid scintillation spectrometry. 
 
4.30. Statistical analysis 
 
Binding and functional parameters were estimated with GraphPAD Prism software 
(GraphPAD, San Diego, CA). IC50 values obtained from competition curves were converted 
to Ki values using the Cheng–Prusoff equation.54 Data were expressed as mean ± standard 
error. 
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Tables
Table 1. Binding affinity (A1R, A2AR, or A3R) or functional activation (A2BR and A3R) of the adenosine derivatives at human adenosine
receptors, n = 3 , unless noted.
NO
N
N
OHR2
R1
N
N
H
R4
R3
Compound R1 R2 R3 R4 hA1ARa hA2AARb hA2BARc hA3ARd
cAMP
hA3ARg
h CH2OH NH2 H H 14% 6% --- 442,000±121,000 53±5
3 CH2OH CH2N3 H H 25% 38% --- 53±1% 1.1±0.9
7 CH2OH CH2NH2 H H 39% 33% --- 43±1% 23±8
4 CH2OH CH2N3 CH3 H 69% 51% --- 20,600e 2.7±1.6
8 CH2OH CH2NH2 CH3 H 42% 22% --- 48±3% 48±6
h CH2OH NH2 3-IB H 93% 70% --- 870±180 ---
5 CH2OH CH2N3 3-IB H 27% 28% --- 61±1% 6.8±1.7
9 CH2OH CH2NH2 3-IB H 72% 22% --- 8700e 9.2±2.1
11 CH2OH CH2NHAc 3-IB H 38% 0% --- 31,500e 20±5
10 CH2OH CH2NH2 CMB H 61% 20% 0% 13,800±1400 18±3
12 CH2OH CH2NHAc CMB H --- --- --- 4%f 1.4±0.2
24 MeUron N3 3-IB H 64% 32% 0% 2260±480 0
27 MeUron NH2 3-IB H 3080±380 67% 20% 137±41 37±5
25 MeUron CH2N3 3-IB H 24% 0% 0% 23±1% 23±4
28 MeUron CH2NH2 3-IB H 52% 6% 0% 1690±330 17±2
26 MeUron N3 3-IB Cl 70% 29% 0% 4270±1400 0
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29 MeUron NH2 3-IB Cl 73% 50% 0% 132±60 30±6
30 MeUron N3 CMB H 66% 34% 13% 376±83 0
32 MeUron NH2 CMB H 8190±750 49% 7% 27±11 51±4
31 MeUron CH2N3 CMB H 54% 43% 19% 755±40 0
33 MeUron CH2NH2 CMB H 52% 2% 2% 557±164 30±6
a Ki (nM) or % inhibition of binding at 100 µM ([3H]R-PIA, 2.0 nM) in CHO cells expressing hA1AR.
b % inhibition of binding at100 µM ([3H]CGS21680,15 nM) in HEK-293 cells expressing hA2AAR.
c % activation (cAMP assay) at100 µM in CHO cells expressing hA2BAR (NECA is 100%).
d Ki (nM) or % inhibition at 100 µM ([125I]I-AB-MECA, 0.5 nM) in CHO cells expressing hA3AR, unless noted
e n = 1.
f at 10 µM.
g % inhibition at 100 µM of forskolin-stimulated cAMP production at 10 µM, in CHO cells expressing the hA3AR, as a percentage of the
responce of the full agonist Cl-IB-MECA (n=2).
h affinities previously reported in ref. 39.
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Table 2. Elemental analysis of evaluated derivatives. 
 calculated %  found % 
Compound C H N  C H N 
3 42.51 4.70 36.05  42.86 4.60 35.84 
4 43.37 5.26 33.72  43.62 4.99 33.55 
5 41.39 3.67 21.45  41.40 4.00 21.11 
6 49.52 4.59 24.31  49.60 4.73 24.11 
7 47.14 5.75 29.98  47.05 5.88 29.64 
8 44.85 6.59 26.15  44.95 6.58 26.35 
941 43.56 4.26 16.93  43.90 4.58 16.60 
10 51.94 5.39 19.13  52.07 5.31 19.13 
11 42.49 4.64 14.86  42.26 4.42 14.53 
12 51.91 5.39 17.29  51.78 5.03 17.11 
2440 38.45 3.76 22.42  38.94 3.51 22.11 
25 39.60 4.02 21.87  39.68 3.87 21.78 
26 37.36 3.13 21.78  37.62 2.94 21.56 
2740 41.71 4.08 18.92  41.82 4.25 18.59 
28 42.51 4.41 18.26  42.83 4.34 17.90 
29 39.76 3.52 18.03  39.47 3.34 17.66 
30 47.26 4.38 26.11  46.94 4.09 26.44 
31 48.34 4.67 25.37  48.52 4.44 29.97 
32 48.05 5.31 20.65  48.27 5.18 20.73 
33 49.13 5.57 20.05  48.86 5.19 19.90 
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Schemes 
 
NO
N
N
OAc
N
Cl
TolO
N3
O
OH
OH
O
O
NO
N
N
OH
N
N
H
OH
N3
R NO
N
N
OH
N
N
H
OH
NH2
R
NO
N
N
OH
N
N
H
OH
N
H
R
O
21
9, 10
Ref. 41
a b
c
R
3 H
4 CH3
5 3-iodobenzyl
6 5-chloro-2-methoxybenzyl
 R
7 H
8 CH3
9 3-iodobenzyl
10 5-chloro-2-methoxybenzyl
 R
11 3-iodobenzyl
12 5-chloro-2-methoxybenzyl  
35 of 37
Thursday , November  18, 2004
Elsevier
Re
vie
w 
Co
py
Bioorg. Med. Chem. 36
O
TolO
O
O
N3
O
O
O
OSi
N3
O
N
H
O
O
R1
O
OAcO
OAc
N
H
R1
O
O
OH
O
O
R113
14
a
b
R1
17  N3
18 CH2N3
R1
19  N3
20 CH2N3
dc
R1
15  N3
16 CH2N3
NO
N
N
OAc
N
Cl
N
H
R1
O
R219, 20
 R1        R2
21  N3 H
22 CH2N3 H
23 N3 Cl
e
NO
N
N
OH
N
N
H
N
H
R1
O
IR2
NO
N
N
OH
N
N
H
N
H
R1
O
IR221 - 23
f g
R1        R2
24  N3 H
25 CH2N3 H
26 N3 Cl
 R1    R2
27  NH2 H
28 CH2NH2 H
29 NH2 Cl
NO
N
N
OH
N
N
H
N
H
R1
O
Cl
O
NO
N
N
OH
N
N
H
N
H
R1
O
Cl
O
21, 22  R1
30  N3
31 CH2N3
R1
32  NH2
33 CH2NH2
f g
a b
O
N
H
O
O
N3
O
17
N
O
OAc
AcO
OAc
N3
4
6
34
N
N
N
N
N
Cl
O
OAcN3
AcO
35  
36 of 37
Thursday , November  18, 2004
Elsevier
Re
vie
w 
Co
py
Bioorg. Med. Chem. 37
Legends 
 
Scheme 1.a
aReagents and conditions: (a) (i) amine HCl (or ammonia for 3), Et3N, EtOH, reflux (ii) 7 N 
NH3 in MeOH, rt; (b) Ph3P, NH4OH, pyridine, rt; (c) CH3COCl, 50% aqueous NaOAc, 
THF,rt. 
 
Scheme 2.a
aReagents and conditions: (a) 0.1 N NaOCH3, MeOH, rt; (b) TBAF, THF, rt; (c) (i) NaIO4,
RuCl3, CHCl3:CH3CN:H2O (2:2:3), rt (ii) dry MeOH, EDC, DMAP, rt (iii) 2 M CH3NH2 in 
THF, 55°C; (d) H2SO4, Ac2O, AcOH, rt; (e) silylated 6-chloropurine or 2,6-dichloropurine, 
TMSOTf, dry 1,2-dichloroethane, reflux; (f) (i) amine HCl, Et3N, EtOH, reflux (ii) 7 N NH3
in MeOH, rt; (g) Ph3P, NH4OH, pyridine, rt. 
 
Scheme 3.a
aReagents and conditions: (a) (i) 70% HOAc, 60°C (ii) Ac2O:pyridine (1:2), rt; (b) silylated 6-
chloropurine, TMSOTf, dry 1,2-dichloroethane, reflux. 
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